Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes

Cytokine

Volumn 12, Issue 7, 2000, Pages 960-971

  Kass, E ^a   Parker, J ^a,c   Schlom, J ^a   Greiner, J W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b c/o Lab of Tum Immunol and Biol ^*  (United States)

^c Biomira   (Canada)

Author keywords

GM CSF; Recombinant vaccinia GM CSF

Indexed keywords

CD11 ANTIGEN; CD19 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BIOASSAY; CANCER IMMUNIZATION; CELL COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FEMALE; FLOW CYTOMETRY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHENOTYPE; PLAQUE FORMING CELL; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0033910714     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2000.0684     Document Type: Article

References (38)

1. Gozdasoglu S, Unal E, Yavuz G, Pamir A, Reisli I, Deda G, Tarcan A, Babacan E, Cavdar AO (1995) Granulocyte-macrophage colony stimulating factor (rh-GM-CSF) in the treatment of chemotherapy-induced neutropenia. J Chemother 7:467-469.
2. Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL (1997) Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple melanoma. J Clin Oncol 15:660-666.
3. Itala M, Vanhatalo S, Temes K (1997) Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukemia: A crossover study. Leukemia and Lymphoma 25:503-508.
4. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci 90:3539-3543.
5. Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified vaccines. Cancer Res 54:1760-1765.
6. Area MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE (1995) Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 3:39-46.
7. Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S (1987) Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen presenting cells. J Immunol 139:1113-1119.
8. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA (1996) Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 88:202-210.
9. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilemann C, Hagedorn M, Oesch F, Knuth A (1996) Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54-62.
10. Chen TT, Tao M-H, Levy R (1994) Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficiency of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775-4787.
11. Kwak LW, Young HA, Pennington RW, Weeks SD (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte-macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci 93:10972-10977.
12. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296.
13. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbech J, Jager D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996) Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54-62.
14. Tarr PE, Lin R, Mueller EA, Kovarik JM, Guillaume M, Jones TC (1996) Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 14:1199-1204.
15. Samanci A, Yi Q, Fagerberg J, Strigard K, Smith G, Ruden U, Wahren B, Mellstedt H (1998) Pharmacological administration of granulocyte-macrophage colony-stimulating factor is of significance importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 47:131-147.
16. Leong SPL, Enders-Zohr P, Zhou Y-M, Stuntebeck S, Habib FA, Allen Jr, RE, Sagebiel RW, Glassberg AB, Lowenberg DW, Hayes FA (1999) Recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22:166-174.
17. Ramsey AJ, Lohonen-Corish M (1993) Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo. Eur J Immunol 23:3141-3145.
18. Leong KH, Ramsey AJ, Boyle DB, Ramshaw IA (1994) Selective induction of immune responses by cytokines co-expressed in recombinant fowlpox virus. J Virol 68:8125-8130.
19. Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BEH (1987) Recovery of immunodeficient mice from a vaccinia virus/IL-2 infection. Nature 329:545-546.
20. Hugin AW, Flexner C, Moss B (1993) Clearance of recombinant vaccinia virus expressing IL-2: Role of local host immune responses. Cell Immun 152:499-509.
21. McLaughlin JP, Abrams SA, Kantor J, Dobrzanski MJ, Greenbaum J, Schlom J, Greiner JW (1997) Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. J Immunother 20:449-459.
22. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D (1980) Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med 52:1036-1047.
23. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner J (1999) Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 59:676-683.
24. Metlay JP, Witmer-Pack MD, Agger R, Crowley MT, Lawless D, Steinman RM (1990) The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med 171:1753-1771.
25. + T cell in vivo. J Immunol 154:5684-5693.
26. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 184:1953-1962.
27. Chen TT, Levy R (1995) Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein. J Immunol 154:3105-3117.
28. McNeel DG, Schiffman K, Disis ML (1999) Immunization with a recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 93:2653-2659.
29. Issekutz TB (1985) Characteristics of lymphoblasts appearing in efferent lymph on response to immunization with vaccinia virus. Immunology 56:23-31.
30. McLaren C, Cheng H, Spicer DL, Tompkins WAF (1976) Lymphocyte and macrophage responses after vaccinia virus infections. Infect Immun 14:1014-1021.
31. Gosselin EJ, Wardell K, Rigby WF, Guyre PM (1993) Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 151:1482-1487.
32. Kalpan G, Walsh G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R (1992) Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175:1717-1728.
33. Agrawal B, Fraga E, Kane K, Singh B (1994) Up-regulation of the MHC class II molecules on B cells by peptide ligands. J Immunol 152:965-975.
34. Rescigno M, Granucci F, Citterio S, Foti M, Ricciardi-Castagnoli P (1999) Coordinated events during bacteria-induced DC maturation. Immunol Today 20:200-203.
35. Miyatake ST, Otsuka T, Yokota T, Lee F, Aria K (1985) Structure of the chromosomal gene for granulocyte-macrophage colony-stimulating factor: comparison of the mouse and human genes. EMBO J 4:2561-2568.
36. Mackett M, Smith GL, Moss B (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci 79:7415-7419.
37. Schott ME, Wells DT, Schlom J, Abrams SI (1996) Comparison of linear and branched peptides forms (MAPS) in the induction of helper responses to point mutated ras immunogens. Cell Immunol 174:199-209.
38. Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552-5555.